SCHEMBL17506539

SCHEMBL17506539

COc1cc(NS(=O)(=O)S(=O)(=O)c2ccc(C)cc2)c2ncccc2c1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.79
MEN1 O00255 5/20 0.79
TDP1 Q9NUW8 5/20 0.79
CXCR2 P25025 2/20 0.79
LMNA P02545 1/20 0.79
TP53 P04637 1/20 0.79
MAPT P10636 1/20 0.79
HPGD P15428 1/20 0.79
TSHR P16473 1/20 0.79
AGTR1 P30556 1/20 0.79
SMN1; SMN2 Q16637 1/20 0.79
NPSR1 Q6W5P4 1/20 0.79
CKS1B P61024 3/20 0.72
SKP2 Q13309 3/20 0.72
POLB P06746 1/20 0.65
SLC40A1 Q9NP59 8/20 0.65
NFKBIA P25963 3/20 0.62
RELA Q04206 2/20 0.62
GLO1 Q04760 1/20 0.55
CXCR4 P61073 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29575795 0.88 KMT2A (1.00) KMT2AMEN1TDP1CXCR2LMNA
SCHEMBL1505430 0.88 KMT2A (1.00) KMT2AMEN1TDP1CXCR2LMNA
SCHEMBL17506515 0.84 HSP90AA1 (0.61) KMT2AMEN1TDP1CXCR2LMNA
SCHEMBL17506531 0.84 CKS1B (1.00) KMT2AMEN1TDP1CXCR2LMNA
SCHEMBL13633886 0.83 MEN1 (1.00) KMT2AMEN1TDP1CXCR2LMNA
SCHEMBL27930114 0.79 SLC40A1 (0.71) KMT2AMEN1TDP1CXCR2LMNA
SCHEMBL22076984 0.79 MEN1 (1.00) KMT2AMEN1TDP1CXCR2LMNA
SCHEMBL7197593 0.79 SLC40A1 (1.00) KMT2AMEN1TDP1CXCR2LMNA
SCHEMBL30925561 0.79 MEN1 (0.74) KMT2AMEN1TDP1CXCR2LMNA
SCHEMBL22111633 0.78 MEN1 (0.84) KMT2AMEN1TDP1CXCR2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3180328-B1 QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS RIGEL PHARMACEUTICALS INC (US) 2020-03-18 EP disclosed
US-10040766-B2 Ubiquitination inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2018-08-07 US disclosed
EP-3180328-A1 QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2017-06-21 EP disclosed
US-20160068490-A1 UBIQUITINATION INHIBITORS MIDCAP FINANCIAL TRUST 2016-03-10 US disclosed
WO-2016025779-A1 QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2016-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068490-A1 UBIQUITINATION INHIBITORS MDM2, RBX1, NEDD4 KMT2A 501/4885MEN1 2624/4885TDP1 2023/4885
US-10040766-B2 Ubiquitination inhibitors MDM2, RBX1, NEDD4 KMT2A 501/4885MEN1 2624/4885TDP1 2023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.